|
Marín F, Roldán V, Lip GY. Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable? Expert Opin Pharmacother. 2012 Jun;13(8):1087-90. doi: 10.1517/14656566.2012.688954. Epub 2012 May 9. PubMed PMID: 22568622.
AÑO: 2012; IF: 2.86
|
22568622
|
Olesen J.B., Pisters R., Roldans V., Marin F., Lane D.A. The ATRIA risk scheme to predict warfarin-associated hemorrhage: Not ready for clinical use. Journal of the American College of Cardiology. 10 January 2012. 59:194-195. 10.1016/j.jacc.2011.08.071
AÑO: 2012; IF: 14.086
|
|
Gallego P, Roldán V, Marín F, Jover E, Manzano-Fernández S, Valdés M, Vicente V, Lip GY. Ankle brachial index as an independent predictor of mortality in anticoagulated atrial fibrillation. Eur J Clin Invest. 2012 Dec;42(12):1302-8. doi: 10.1111/eci.12004. Epub 2012 Oct 11. PubMed PMID: 23057651.
AÑO: 2012; IF: 3.365
|
|
Ruiz-Nodar JM, Marín F, Roldán V, Valencia J, Manzano-Fernández S, Caballero L, Hurtado JA, Sogorb F, Valdés M, Lip GY. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? Circ Cardiovasc Interv. 2012 Aug 1;5(4):459-66. doi: 10.1161/CIRCINTERVENTIONS.112.968792. Epub 2012 Jul 10. PubMed PMID: 22787018.
AÑO: 2012; IF: 6.543
|
|
Tello-Montoliu A, Jover E, Rivera J, Valdés M, Angiolillo DJ, Marín F. New perspectives in antiplatelet therapy. Curr Med Chem. 2012;19(3):406-27. Review. PubMed PMID: 22335515.
AÑO: 2012; IF: 4.07
|